

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortage for Sandoz Morphine SR 15 mg Sustained-Release Tablet (DIN 02244790) and Teva-Morphine SR 15 mg Sustained-Release Tablet (DIN 02302764) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 5, 2022**. The following grouping was removed from the Critical Supply Product List **December 6, 2021**.

MORPHINE SULPHATE

15 MG SUSTAINED-RELEASE TABLET

00002244790	SANDOZ MORPHINE SR	SDZ	\$ 0.4145
00002302764	TEVA-MORPHINE SR	TEV	\$ 0.4145
00002015439	MS CONTIN	PUR	\$ 0.7700

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Amitriptyline 50 mg Tablet (DIN 02403153) manufactured by Apotex Inc. and Elavil 50 mg Tablet (DIN 00335088) manufactured by AA Pharma Inc., pms-Amitriptyline 50 mg Tablet (DIN 00654507) and Mar-Amitriptyline 50 mg Tablet (DIN 02429896) will be considered as temporary benefits for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **December 3, 2021**.

As of **December 3, 2021**, all claims for pms-Amitriptyline 50 mg Tablet (DIN 00654507) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

As of **December 7, 2021**, all claims for Mar-Amitriptyline 50 mg Tablet (DIN 02429896) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

continued next page

PHARMACY BENEFACT

continued from previous page

Due to the unavailability of Apo-Amitriptyline 25 mg Tablet (DIN 02403145) manufactured by Apotex Inc. and Elavil 25 mg Tablet (DIN 00335061) manufactured by AA Pharma Inc., Mar-Amitriptyline 25 mg Tablet (DIN 02429888) will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **October 29, 2021**.

As of **December 7, 2021**, all claims for Mar-Amitriptyline 25 mg Tablet (DIN 02429888) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Removal of temporary benefit from the *Palliative Coverage Drug Benefit Supplement (PCDBS)*

Due to the shortage of Senokot S 8.6 mg / 50 mg Tablet (DIN 00026123) manufactured by Purdue Pharma, Senna Laxative & Docusate Sodium 8.6 mg / 50 mg Tablet (DIN 02247134) manufactured by Vita Health Products Inc., was added as a temporary benefit for the *Palliative Coverage Drug Benefit Supplement (PCDBS)*.

Purdue Pharma has advised Alberta Blue Cross that the shortage of Senokot S 8.6 mg / 50 mg Tablet (DIN 00026123) has been resolved.

As a result, Senna Laxative & Docusate Sodium 8.6 mg / 50 mg Tablet (DIN 02247134) will no longer be considered as a temporary benefit for the *PCDBS* after **January 12, 2022**. The above grouping was removed from the Critical Supply Product List **December 13, 2021**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](https://www.ab.bluecross.ca/providers/pharmacy-home.php)

